Drugs / Pelubiprofen
Pelubiprofen
also known as
PELUBI tab. · 2-[4-(oxocyclohexylidenemethyl)-phenyl]propionic acid · CS-670 · Pelubi · Pelubi CR · Pelubiprofen IR · Pelubiprofen SR · Pelubiprofene · +2 more
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07032558 | Sep 2025 overdue | — | Haiphong University of Medicine and Pharmacy | Recruiting | No outcome recorded |
| Phase 1 | NCT07060209 | Sep → Oct 2025 overdue | — | Haiphong University of Medicine and Pharmacy | Recruiting | No outcome recorded |
| Phase 1 | NCT05214677 | Aug → Sep 2020 | osteoarthritis, respiratory tract infectious disorder, rheumatoid arthritis | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05214690 | Aug → Sep 2020 | osteoarthritis, respiratory tract infectious disorder, rheumatoid arthritis | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01776697 | Mar → Apr 2012 | — | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 34 trials · 2 met primary | ||||||
| Phase 3 | NCT04541134 | Sep 2020 → Aug 2021 | primary dysmenorrhea | Daewon Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03874247 | Feb → Dec 2019 | — | Daewon Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT01779271 | Jan 2013 → Mar 2016 | respiratory tract infectious disorder | Daewon Pharmaceutical Co., Ltd. | Completed | Met primary |
| Phase 3 | NCT01781702 | Oct 2010 → Oct 2011 | rheumatoid arthritis | Daewon Pharmaceutical Co., Ltd. | Completed | Met primary |
| Comparator or background therapy4 trials | ||||||
| Phase 1 | NCT01870102 Comparator | ? → Aug 2013 | — | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT03424707 Comparator | Mar → Aug 2016 | — | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02375633 Comparator | Apr → Nov 2014 | chronic pain syndrome | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT02682524 Comparator | Aug 2015 → Mar 2016 | osteoarthritis, knee | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-10-08 | Daewon Pharmaceutical Co., Ltd. | Results 대원제약, KOA 2026서 ‘펠루비’ 수술 후 통증 조절 신규 연구 발표 daewonpharm.com ↗
두 군 간 차이는 0.2mm(95% 신뢰구간 -4.4~4.8mm)로, 신뢰구간 상한이 사전에 설정한 비열등성 한계인 10mm를 넘지 않아 펠루비프로펜의 통증 조절 효과가 셀레콕시브 대비 비열등한 것으로 확인됐다. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-10-08 | Daewon Pharmaceutical Co., Ltd. | 대원제약, KOA 2026서 ‘펠루비’ 수술 후 통증 조절 신규 연구 발표 daewonpharm.com ↗ |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pelubiprofen | “DW-1021 is a fixed-dose combination tablet containing Pelubiprofen 45 mg and Tramadol 45.9 mg (as a salt), formulated as a controlled-release film-coated tablet.” NCT07032558 ↗12“A fixed-dose combination controlled release film-coated tablet containing pelubiprofen 45 mg and tramadol 45.9 mg (salt form)” NCT07060209 ↗ “pelubiprofen 30mg (PELUBI tab.)” NCT05214677 ↗ “pelubiprofen 25mg” NCT05214690 ↗ |
| Known as | 2-[4-(oxocyclohexylidenemethyl)-phenyl]propionic acid | “Anti-inflammatory effect of pelubiprofen, 2-[4-(oxocyclohexylidenemethyl)-phenyl]propionic acid, mediated by dual suppression of COX activity and LPS-induced inflammatory gene...” PMID 21809372 ↗ Dec 2011 |
| Known as | CS-670 | ChEMBL registry synonym — accepted as the source's own label CHEMBL69308 ↗ |
| Known as | Pelubi | “Pelubi(pelubiprofen)” NCT03424707 ↗ |
| Known as | Pelubi CR | “The reference treatment consists of two separate controlled-release film-coated tablets: Pelubi CR (Pelubiprofen 45 mg) and Zytram CR (Tramadol HCl 75 mg).” NCT07032558 ↗ |
| Known as | PELUBI tab. | “pelubiprofen 30mg (PELUBI tab.)” NCT05214690 ↗1“pelubiprofen 30mg (PELUBI tab.)” NCT05214677 ↗ |
| Known as | Pelubiprofen IR | “Pelubiprofen IR (Pelubiprofen 30mg) TID” NCT01870102 ↗ |
| Known as | Pelubiprofen SR | “Pelubiprofen SR (Pelubiprofen 45 mg) BID” NCT01870102 ↗ |
| Known as | Pelubiprofene | ChEMBL registry synonym — accepted as the source's own label CHEMBL69308 ↗ |
| Known as | Pelubiprofeno | ChEMBL registry synonym — accepted as the source's own label CHEMBL69308 ↗ |
| Known as | RS-2131 | ChEMBL registry synonym — accepted as the source's own label CHEMBL69308 ↗ |
| Action | Inhibit | “pelubiprofen potently diminished PGE(2) productions through inhibition of COX enzyme activity” PMID 21809372 ↗ Dec 2011 |
| Modality | Small molecule | — CHEMBL69308 ↗ |
| Route | Oral | “It is administered as a single oral dose with 150 mL of water under fasting conditions for the evaluation of pharmacokinetics in healthy adult male volunteers.” NCT07032558 ↗ |